• 关于我们
    • 公司简介
    • 组织架构
    • 成立沿革
    • 经营团队
    • 核心价值
    • 投资策略及焦点
  • 投资组合
  • 新闻中心
    • 相关新闻
    • 重大讯息
  • 企业永续
    • 永续报告书
    • 永续经营
    • 治理永續
    • 责任投资
    • 环境永续
    • 社会永续
  • 投资人专区
    • 公司治理
    • 股东专区
    • 投资人提问
  • 人力资源
    • 选择钻石
    • 学习发展
    • 薪酬福利
    • 加入钻石
  • 联络我们
  • Language
    • 繁
    • EN
    • 簡
  • 关于我们
    • 公司简介
    • 组织架构
    • 成立沿革
    • 经营团队
    • 核心价值
    • 投资策略及焦点
  • 投资组合
  • 新闻中心
    • 相关新闻
    • 重大讯息
  • 企业永续
    • 永续报告书
    • 永续经营
    • 治理永續
    • 责任投资
    • 环境永续
    • 社会永续
  • 投资人专区
    • 公司治理
    • 股东专区
    • 投资人提问
  • 人力资源
    • 选择钻石
    • 学习发展
    • 薪酬福利
    • 加入钻石
  • 联络我们
  • Language
    • 繁
    • EN
    • 簡
14
12 月
2024, 新析生物科技股份有限公司, 相关新闻
钻石生技 > 2024 > Syncell 的 Microscoop® 荣登《The Scientist》2024 年度十大创新榜单

相关新闻依年度

  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
2024-12-14

Syncell 的 Microscoop® 荣登《The Scientist》2024 年度十大创新榜单

分享

發布日期:2024-12-14

原始連結:https://www.diamondbiofund.com/tc/news_detail537_1.htm


2024-12-14

钻石生技于2023年投资Syncell(新析生技),Syncell是2020年由中央研究院团队所衍生新创,发展领域为空间生物学,其核心技术平台 Microscoop® (光标靶仪)是世界上第一个“可抓取式”显微镜,应用人工智慧演算法,从指定的细胞位置,可选择性地抓取蛋白质和核酸进行分析,这项技术于今年(2024年)荣登《The Scientist》2024 年度十大创新榜单,凸显其在生命科学领域的技术领先地位。

Syncell’s Microscoop® Named One of The Scientist’s Top 10 Innovations of the Year

TAIPEI, Taiwan & WATERTOWN, Mass. – December 13, 2024 – Syncell, a leader in next-generation subcellular protein purification and spatial proteomics analysis, today announced that its Microscoop® was named #5 on The Scientist’s prestigious list of “Top Innovations of 2024.” The list, unveiled today, highlights groundbreaking advancements and tools driving progress in life sciences and biotechnology.

“Our Microscoop platform represents a groundbreaking approach to spatial proteomics, providing researchers with the precision and sensitivity needed to uncover new insights into biological processes,” said Jung-Chi Liao, founder and CEO of Syncell. “We are honored to be recognized by The Scientist for our unique approach to helping researchers take their protein research further, by bringing together different technologies to build innovative models of biology that were previously out of reach.

” Syncell’s Microscoop is an innovative platform designed to enable unbiased spatial proteomic discovery at the disease site, delivering unparalleled precision in identifying novel protein components from targeted regions of interest (ROIs). Utilizing microscopy-guided photochemistry, the Microscoop system photolabels proteins within user-defined ROIs in cells or tissues, enabling the precise extraction of proteins from tens of thousands of fields of view (FOVs) with similar morphological features. This unique capability allows researchers to perform hypothesis-free subcellular protein analysis with exceptional sensitivity and specificity, uncovering both known and novel protein constituents within subcellular structures. By offering unprecedented insights into site-specific proteomes, Microscoop empowers a wide range of biological and translational research.

The Microscoop platform is the first of its kind to combine photochemistry, microscopy, artificial intelligence-driven image processing, mechatronics, and biochemistry into a streamlined and user-friendly system. This enables precise, high-throughput, image-guided protein labeling at submicron resolution, allowing scientists to spatially label and analyze proteins in individual cells or subcellular regions. Photolabeled proteins are extracted and analyzed with mass spectrometry to reveal thousands of known and novel proteins players in disease-relevant or biologically significant ROIs.
By providing a unique and precise approach to spatial proteomics, Microscoop equips researchers with the ability to map and discover the proteomic landscape of cellular and subcellular environments, opening new frontiers in disease research and therapeutic innovation.

To learn more about Microscoop technology, visit www.Syncell.com.


About Syncell

Syncell is a commercial stage life science company focused on subcellular protein purification and spatial proteomics analysis. The company was founded in 2020 leveraging technology developed by founder and CEO Jung-Chi Liao at Academia Sincia laboratory in Taiwan. Headquartered in Taipei, Taiwan and Watertown, Mass., Syncell has commercialized its Microscoop® technology, helping researchers achieve unbiased discovery in spatial proteomics at the disease site, with the ability to accurately discover new protein components from targeted regions of interest. To date, the company has raised $30 million from investors. To learn more, visit www.Syncell.com or follow us on Linkedin.

SOURCE

PrevNext

公司資訊

電話 : 02-2703-1338

地址 : 100 台北市中正區忠孝西路一段66號34樓

投資人聯絡窗口

許心婷 小姐

專線 : 02-2703-1068

关于我们

  • 公司简介
  • 组织架构
  • 成立沿革
  • 经营团队
  • 核心价值
  • 投资策略及焦点

投资组合

新闻中心

  • 相关新闻
  • 重大消息

投资人专区

  • 公司治理
  • 股东专区

人力资源

  • 选择钻石
  • 學習發展
  • 薪酬福利
  • 加入钻石

联络我们

醣基生醫股份有限公司

醣基生醫股份有限公司
2017年9月27日登錄興櫃市場交易 (6586:TT)
公司所在地
台北,台灣
公司設立日期
2013
登錄公開市場
2017
公司官網
https://www.chopharma.com/cn/index.html

 

尹衍梁创投 入股美商永生

基龙米克斯、华大基因 策略联盟

生技首例 美商永生明年Q3上柜

醣基生医研发之醣抗原抗体抗癌新药(CHO-A04)临床申请案,接获美国食品药物管理局(FDA)同意进行第一期人体临床试验

对抗超级细菌!醣基生医创新疫苗携手润雅生技CDMO迈临床一期

醣基生医 CHOptimax 获得最佳技术平台奖项肯定